Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 04/16/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. NUVL, GRFS, ELAN, VRNA, ADMA, CYTK, PCVX, RYTM, PTCT, and OGNShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Nuvalent (NUVL), Grifols (GRFS), Elanco Animal Health (ELAN), Verona Pharma (VRNA), ADMA Biologics (ADMA), Cytokinetics (CYTK), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Nuvalent Grifols Elanco Animal Health Verona Pharma ADMA Biologics Cytokinetics Vaxcyte Rhythm Pharmaceuticals PTC Therapeutics Organon & Co. Nuvalent (NASDAQ:NUVL) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Which has better valuation & earnings, NUVL or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Nuvalent. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$126.22M-$3.90-18.23Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Do institutionals and insiders hold more shares of NUVL or CALT? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 12.5% of Nuvalent shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor NUVL or CALT? In the previous week, Nuvalent had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Nuvalent and 0 mentions for Calliditas Therapeutics AB (publ). Nuvalent's average media sentiment score of 1.32 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Nuvalent is being referred to more favorably in the media. Company Overall Sentiment Nuvalent Positive Calliditas Therapeutics AB (publ) Neutral Do analysts rate NUVL or CALT? Nuvalent presently has a consensus price target of $115.50, suggesting a potential upside of 62.42%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, suggesting a potential downside of 1.88%. Given Nuvalent's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvalent is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, NUVL or CALT? Nuvalent has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Does the MarketBeat Community favor NUVL or CALT? Nuvalent received 18 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 78.95% of users gave Nuvalent an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformNuvalentOutperform Votes4578.95% Underperform Votes1221.05% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Is NUVL or CALT more profitable? Nuvalent has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Nuvalent's return on equity of -28.63% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -28.63% -27.15% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% SummaryNuvalent beats Calliditas Therapeutics AB (publ) on 14 of the 18 factors compared between the two stocks. Remove Ads Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.42B$5.28B$7.33BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-21.626.7921.7017.71Price / Sales0.74225.58376.8193.06Price / CashN/A65.6738.1534.64Price / Book37.745.826.383.95Net Income-$43.96M$142.01M$3.20B$247.42M7 Day PerformanceN/A6.87%4.39%3.83%1 Month PerformanceN/A-14.73%-10.03%-8.16%1 Year Performance113.45%-10.15%10.61%0.86% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180NUVLNuvalent1.721 of 5 stars$64.68-1.6%$113.44+75.4%+8.1%$4.63BN/A-18.6440Positive NewsGRFSGrifols3.1387 of 5 stars$6.55-1.5%N/A+3.7%$4.50B$7.21B5.6026,300Gap UpELANElanco Animal Health4.3479 of 5 stars$8.95-2.2%$15.17+69.6%-40.3%$4.44B$4.44B22.369,800Analyst ForecastVRNAVerona Pharma2.9065 of 5 stars$54.30+0.7%$69.14+27.3%+259.9%$4.39B$42.28M-28.2830Positive NewsGap DownHigh Trading VolumeADMAADMA Biologics1.8935 of 5 stars$18.40+2.2%$22.50+22.3%+244.6%$4.35B$426.45M65.71530Options VolumeNews CoveragePositive NewsCYTKCytokinetics3.7716 of 5 stars$35.99-3.7%$82.00+127.8%-43.3%$4.26B$18.47M-6.69250Analyst ForecastInsider TradeNews CoverageHigh Trading VolumePCVXVaxcyte3.2719 of 5 stars$32.51+2.9%$136.50+319.9%-53.2%$4.19BN/A-7.07160Positive NewsHigh Trading VolumeRYTMRhythm Pharmaceuticals3.8274 of 5 stars$54.96+17.1%$73.31+33.4%+59.2%$3.47B$130.13M-12.69140Analyst RevisionHigh Trading VolumePTCTPTC Therapeutics3.8944 of 5 stars$42.82-1.0%$63.77+48.9%+83.5%$3.38B$806.78M-7.211,410Upcoming EarningsShort Interest ↑Positive NewsOGNOrganon & Co.4.7991 of 5 stars$12.54-3.9%$20.80+65.9%-39.2%$3.23B$6.40B3.7610,000Short Interest ↓ Remove Ads Related Companies and Tools Related Companies Nuvalent Alternatives Grifols Alternatives Elanco Animal Health Alternatives Verona Pharma Alternatives ADMA Biologics Alternatives Cytokinetics Alternatives Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives PTC Therapeutics Alternatives Organon & Co. Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CALT Stock Free CALT Stock Alerts